Home

blanc Christian stéréo kidney cancer biological markers camarade autre chien

Comprehensive molecular characterization of clear cell renal cell carcinoma  | Nature
Comprehensive molecular characterization of clear cell renal cell carcinoma | Nature

An Immune Atlas of Clear Cell Renal Cell Carcinoma - ScienceDirect
An Immune Atlas of Clear Cell Renal Cell Carcinoma - ScienceDirect

Prognostic and predictive biomarkers in Renal Cell Carcinoma. | Download  Table
Prognostic and predictive biomarkers in Renal Cell Carcinoma. | Download Table

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5),  XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal  cell carcinoma | Journal of Experimental & Clinical Cancer Research
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research

Renal cancer biomarkers: the promise of personalized care | BMC Medicine |  Full Text
Renal cancer biomarkers: the promise of personalized care | BMC Medicine | Full Text

A renal cell carcinoma tumorgraft platform to advance precision medicine -  ScienceDirect
A renal cell carcinoma tumorgraft platform to advance precision medicine - ScienceDirect

Frontiers | IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell  Carcinoma and Prediction of Patient Survival
Frontiers | IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5),  XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal  cell carcinoma | Journal of Experimental & Clinical Cancer Research
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5),  XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal  cell carcinoma | Journal of Experimental & Clinical Cancer Research
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research

Determinants of renal cell carcinoma invasion and metastatic competence |  Nature Communications
Determinants of renal cell carcinoma invasion and metastatic competence | Nature Communications

Frontiers | Targeting the Tumor Microenvironment in Renal Cell Cancer  Biology and Therapy
Frontiers | Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy

Diseases | Free Full-Text | Proficient Novel Biomarkers Guide Early  Detection of Acute Kidney Injury: A Review
Diseases | Free Full-Text | Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review

Frontiers | The Identification of Immunological Biomarkers in Kidney Cancers
Frontiers | The Identification of Immunological Biomarkers in Kidney Cancers

Exosomes as a Multicomponent Biomarker Platform in Cancer: Trends in Cancer
Exosomes as a Multicomponent Biomarker Platform in Cancer: Trends in Cancer

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and  Angiogenesis Blockade - ScienceDirect
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade - ScienceDirect

Cancers | Free Full-Text | From Immunohistochemistry to New Digital  Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer  Medicine
Cancers | Free Full-Text | From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine

Cabozantinib Slows Progression of Rare Kidney Cancer - NCI
Cabozantinib Slows Progression of Rare Kidney Cancer - NCI

How are biomarkers used to treat cancer? | MD Anderson Cancer Center
How are biomarkers used to treat cancer? | MD Anderson Cancer Center

Tumor and immune reprogramming during immunotherapy in advanced renal cell  carcinoma - ScienceDirect
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma - ScienceDirect

Mapping the immune environment in clear cell renal carcinoma by single-cell  genomics | Communications Biology
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics | Communications Biology

Biomarkers in renal cell carcinoma: Are we there yet? - ScienceDirect
Biomarkers in renal cell carcinoma: Are we there yet? - ScienceDirect

Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis:  What Can Be Implemented in Our Practice Today? A Systematic Review of the  Literature - ScienceDirect
Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature - ScienceDirect

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5),  XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal  cell carcinoma | Journal of Experimental & Clinical Cancer Research
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research

Biomarkers in drug discovery and development
Biomarkers in drug discovery and development

Frontiers | Predictive Biomarkers of Response to Immunotherapy in  Metastatic Renal Cell Cancer
Frontiers | Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer

Urine Proteome Profiling Predicts Lung Cancer from Control Cases and Other  Tumors - eBioMedicine
Urine Proteome Profiling Predicts Lung Cancer from Control Cases and Other Tumors - eBioMedicine

Frontiers | The Identification of Immunological Biomarkers in Kidney Cancers
Frontiers | The Identification of Immunological Biomarkers in Kidney Cancers